SCHEMBL7989569

SCHEMBL7989569

Cc1cc(-c2c(C#N)c(NC[C@H](O)CO)nc(SCc3coc(-c4ccc(Cl)cc4)n3)c2C#N)[nH]n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 11/20 0.43
MAPT P10636 3/20 0.34
NPSR1 Q6W5P4 3/20 0.34
LMNA P02545 2/20 0.34
NPC1 O15118 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 2/20 0.33
TAAR1 Q96RJ0 1/20 0.33
SLC6A3 Q01959 1/20 0.32
ADORA2A P29274 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12376566 0.92 ADORA1 (0.37) ADORA1MAPTNPSR1LMNANPC1
SCHEMBL7999946 0.86 ADORA1 (0.49) ADORA1SLC6A3
SCHEMBL8002661 0.84 ADORA1 (0.44) ADORA1MAPTNPSR1LMNANPC1
SCHEMBL7998996 0.83 ADORA1 (0.51) ADORA1MAPTNPSR1LMNANPC1
SCHEMBL1931331 0.82 ADORA1 (0.51) ADORA1MAPTALDH1A1HPGDKDM4E
SCHEMBL12376503 0.80 ADORA1 (0.41) ADORA1MAPTNPSR1LMNANPC1
SCHEMBL8003034 0.78 ADORA1 (0.42) ADORA1MAPTNPSR1LMNANPC1
SCHEMBL12376558 0.78 ADORA1 (0.46) ADORA1SLC6A3
SCHEMBL12163893 0.78 ADORA1 (0.42) ADORA1MAPTNPSR1LMNANPC1
SCHEMBL12376542 0.77 ADORA1 (0.45) ADORA1MAPTNPSR1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274299-B1 HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF FOR TREATMENT OF CARDIOVASCULAR DISEASES BAYER IP GMBH (DE) 2016-06-15 EP disclosed
US-8426602-B2 Heteroaryl-substituted dicyanopyridines and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-04-23 US disclosed
US-20110207698-A1 HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-25 US disclosed
WO-2009112155-A1 HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF FOR TREATMENT OF CARDIOVASCULAR DISEASES BAYER SCHERING PHARMA AG (DE) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207698-A1 HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE QDPR, TNNI3, SDHA ADORA1 3151/4885MAPT 4142/4885NPSR1 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.